Drugs / Crocin

Trials 4 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04936490 Jul → Nov 2021 central serous chorioretinopathy Shiraz University of Medical Sciences Unknown No outcome recorded
Phase 31 trial
Phase 3 NCT03375814 Jul 2016 → Mar 2018 osteoarthritis, knee Mashhad University of Medical Sciences Unknown No outcome recorded
Phase not applicable2 trials
NCT05696665 Jul 2022 → Jul 2023 Parkinson disease, neurodegenerative disease Jinnah Postgraduate Medical Centre Unknown No outcome recorded
NCT05504148 Mar 2021 → Jun 2023 breast cancer Qilu Hospital of Shandong University Unknown No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as Crocin ClinicalTrials.gov intervention name — accepted as the source's own label NCT03375814
3

NCT04936490

NCT05504148

NCT05696665

Known as .alpha.-crocin ChEMBL registry synonym — accepted as the source's own label CHEMBL446785
Known as Crocetin di(beta-gentiobiosyl)ester ChEMBL registry synonym — accepted as the source's own label CHEMBL446785
Known as Crocetin di-gentiobiose ester ChEMBL registry synonym — accepted as the source's own label CHEMBL446785
Known as Crocin 1 ChEMBL registry synonym — accepted as the source's own label CHEMBL446785
Action Inhibit “These results support that Crocin is a effective inhibitor of E46K α-synuclein fibrillization and it could be considered as a potential therapeutic agent in the treatment of...” PMID 31111370 May 2019
Modality Small molecule “Crocin is a carotenoid chemical compound of saffron that has been shown antioxidant and neural protective activity.” PMID 31111370 May 2019
Route Oral “Crocina tablets will be prescribed to the first group a tablet 15 mg daily along with conventional Medicines;” NCT03375814